Emvision Medical Devices Ltd has released a press release.
Emu Pivotal Validation Trial Commences
Filed with ASX ·
6ix hasn’t read this filing yet.
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- First Responder Scanner in Successful Aeromedical Testing
- S&P DJI Announces March 2025 Quarterly Rebalance
- EMVision Releases its FY25 Half Yearly Report
- US Ethics Approval Received for Pivotal Validation Trial
- EMVision Receives $2.12m R&D Tax Rebate
Later from EMvision Medical Devices
- Activation of Second US Pivotal Trial Site, Mayo Clinic
- Enhanced Algorithm Performance From Continuous Innovation
- Additional Pivotal Trial Site Activations
- EMVision Awarded $5m Non-Dilutive Government Grant
- Key Developments in Pivotal Trial & Innovation Study
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices